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Abstract. Background: The relationship between hospital volume and out-
comes needs to be further elucidated for low-risk procedures such as surgical
therapy of localized breast cancer. The objective of this investigation was to
assess the relationship between hospital volume and outcomes for breast
cancer surgery. Methods: A total of 233,247 patients who underwent breast-
conserving therapy (BCT) and breast-ablative therapy (BAT) for localized
breast cancer were extracted from 13 years (1988–2000) of the Nationwide
Inpatient Samples. Hospital volume was classiﬁed as low (<30 cases/year),
intermediate (‡ 30 to <70cases/year), and high (‡ 70 cases/year). Multiple
linear and logistic regression analyses were used to assess the risk-ad-
justed association between hospital volume and outcomes. Results: In
risk-adjusted analyses, patients operated on at low-volume hospitals were
3.04 (p = 0.03) times more likely to die after BCT compared with patients
operated on at high-volume hospitals. Similarly, low-volume hospitals
had a significantly higher likelihood of postoperative complications (odds
ratio [OR] = 1.73, p = 0.01 for BCT; OR = 1.44, p < 0.001 for BAT)
compared with high-volume hospitals. Compared with low-volume hos-
pitals, length of hospital stay was significantly shorter and nonroutine
patient discharge significantly lower for high-volume providers for both
BCT and BAT (all p < 0.001). Patients were also significantly less likely to
undergo BCT if operated on in a low- or intermediate-volume hospital
compared with a high-volume provider (p < 0.001). Conclusions: High-
volume hospitals had significantly lower nonroutine patient discharge,
postoperative morbidity and mortality, shorter length of hospital stay,
and higher likelihood of performing BCT. Referral of patients with
localized breast cancer to high-volume hospitals may be justified.
The relationship between hospital volume and outcomes has
come to the forefront of public debate in recent years. Many
studies have attempted to address this relationship for a broad
range of surgical diseases [1–4]. The majority of these studies
involving cancer patients have evaluated high-risk procedures
which are associated with high mortality rates [3]. In contrast, the
volume–outcomes relationship for routinely performed low-risk
procedures such as breast-conserving therapy (BCT) or mastec-
tomy has been poorly studied.
The aging of our population results in increased incidence of
breast cancer and subsequent surgical treatment. The current
surgical management of localized breast cancer includes BCT and
breast-ablative therapy (BAT). Both procedures carry a low risk
for morbidity and mortality. A few studies to date have evaluated
long-term patient survival, assessing the combination of medical
and surgical care [5–7]. However, to our knowledge no investi-
gation has assessed perioperative outcomes for breast cancer
patients undergoing BCT and BAT. We thus performed an
analysis of over 233,000 patients from 13 consecutive years of the
Nationwide Inpatient Samples database to evaluate the associa-
tion between hospital volume and in-hospital morbidity and
mortality, length of stay, discharge status, and the likelihood of
undergoing BCT. Our a priori hypothesis was that high-volume
hospitals have better outcomes compared with intermediate- and
low-caseload providers.
Materials and Methods
Database Description.
The Nationwide Inpatient Samples for the years 1988 through
2000 were used for this study [8]. The Nationwide Inpatient
Samples are part of the Healthcare Cost and Utilization Project
(HCUP), sponsored by the Agency for Healthcare Research
and Quality (AHRQ) and is among the largest publicly avail-
able inpatient databases in the United States, containing 5–8
million records of inpatient stays. Patients are sampled from
about 750 to 1000 US community hospitals each year. The
Nationwide Inpatient Samples approximate 20% stratified
probability samples representative of community hospitals in the
United States. To ensure maximal representativeness of the US
population, sampling strata were used for the creation of the
Nationwide Inpatient Samples based on five hospital charac-
teristics (geographic region, ownership, urban/rural location,
teaching status, and bed size). The datasets provide the fol-
lowing information: hospital identifiers, patient demographics,
length of hospital stay, vital status, patient discharge status, and
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procedure and diagnoses codes classified according to the
International Classification of Diseases, 9th ed. Clinical Modi-
fication (ICD-9-CM).
The HCUP assigned validation and quality assessment of these
datasets to an independent contractor [8]. The validation was
performed by reviewing univariate statistics for all numeric data
elements, reviewing frequency distributions for all categorical and
some continuous data elements, checking ranges against standard
norms, and performing edit checks to identify inconsistencies
between related data elements. Furthermore, the Nationwide
Inpatient Samples compared favorably with the National Hospital
Discharge Survey (NHDS), and was described to perform very
well for many estimates [9, 10].
Sample Selection
Patients were included in the present analysis if they were
female and had either BCT (ICD-9 codes 85.21, 85.22, 85.23)
or BAT (ICD-9 codes 85.41, 85.43) for breast cancer (ICD-9
codes 174.0, 174.1, 174.2, 174.3, 174.4, 174.5, 174.6, 174.8,
174.9). Breast cancer patients who underwent bilateral breast
cancer surgery (ICD-9 codes 85.42, 85.44, 85.46, 85.48, or two
of the following procedure codes occurring in any combina-
tion: 85.21, 85.22, 85.23), radical mastectomy (ICD-9 code
85.45), or extended radical mastectomy (ICD-9 code 85.47)
were excluded from our investigation. Also, patients with
metastatic disease (except to regional lymph nodes: ICD-9
code 196.3) were excluded. The exclusion criteria were applied
to impart homogeneity to our patient population. We per-
formed stratified analyses based on whether BCT or BAT was
performed.
Outcome Measures
The outcomes of interest included length of hospital stay, non-
routine patient discharge, postoperative in-hospital complica-
tions, all-cause in-hospital mortality, and the likelihood of
undergoing BCT. Length of hospital stay (measured in days) was
defined as the difference between date of admission and date of
discharge of the patient. All-cause, nonfatal in-hospital morbidity
assessed based on ICD-9 diagnoses codes.
Complications included mechanical wound complications,
infections, and complications occurring during the procedure
(Appendix). All-case in-hospital mortatliy was assessed based on
information regarding vital status at discharge.
Another end point that was assessed in the present investi-
gation was the patients discharge status. The Nationwide
Inpatient Samples provide the following information regarding a
patients discharge status: (1) routine discharge from the hos-
pital, (2) discharge to another hospital, (3) discharge to a
nursing facility, (4) discharge to intermediate care, (5) discharge
to another type of facility, (6) discharge to home with home
health care, (7) discharge against medical advice, (8) death.
Patients who died during hospitalization (n = 214, 0.09%) and
patients who left the hospital against medical advice (n = 89,
0.04%) were excluded from the analysis of this specific end
point. The remaining patients were divided into routine dis-
charge (the desired outcome) versus nonroutine discharge (a
negative outcome).
Finally, the likelihood of a patient undergoing BCT versus BAT
was also assessed.
Primary Predictor Variable
The primary predictor variable was annual hospital volume. Each
hospital had a unique hospital identifier which was used to cal-
culate hospital volume separately for BCT and BAT. Hence,
hospital volume reflects only surgical volume of BCT and BAT
and not total surgical volume.
Hospital volume was divided into three categories (low volume:
< 30, intermediate volume: ‡ 30 to < 70, and high volume: ‡ 70
procedures/year). These categories were chosen to obtain ap-
proximately similar percentages of procedures in each category
and also to have clinically meaningful cutoffs.
Covariates
Covariates obtained from the Nationwide Inpatient Samples in-
cluded age (years), race, household income (median household
income of patients ZIP code, 3 categories: 1 $1–25,000,
2 = 25,001–35,000, 3 = 35,001 and above, a known proxy for a
patients socioeconomic status), teaching status and location of
hospital (rural nonteaching, urban nonteaching, urban teaching
hospital), and patients comorbidity (Charlson index modified by
Deyo) [11, 12]. The Charlson index modified by Deyo measures
comorbidity by assigning scores of 1, 2, 3, or 6 to each of a patients
comorbid conditions. These scores are then added up to a single
index score, which reflects the overall comorbidity of the patient.
The hospitals teaching status was obtained from the AHA Annual
Survey of Hospitals. A hospital is considered to be a teaching
hospital if it has an AMA-approved residency program, is a member
of the Council of Teaching Hospitals (COTH), or has a ratio of full-
time equivalent interns and residents to beds of 0.25 or higher [8].
Statistical Analysis
Each of the analyses mentioned below was performed separately
for both BCT and BAT procedures. Bivariate analyses were per-
formed to assess the unadjusted association between hospital vol-
ume and outcomes. Multivariable regression analyses were used to
examine the risk-adjusted association between hospital volume and
outcomes. All multivariable analyses were adjusted for the fol-
lowing potential confounders: age, race, household income,
teaching status and location of the hospital, and patient comor-
bidity. Multivariable regression analyses allow the assessment of
the risk-adjusted (independent of other potential confounders)
impact of hospital volume on the outcomes. Differences between
the potential confounders are thus decreased using this method.
Risk-adjusted odds ratios with 95% confidence intervals (CI)
and p values were used to assess the strength of the association
between hospital volume and the outcomes. Adjusted estimates
were calculated for length of stay using linear regression.
Statistical analyses were conducted using Intercooled STATA
for Windows (version 7.0) (Stata Corporation, College Station, TX)
and SAS for Windows (version 8.02) (SAS Institute Inc., Cary, NC).
Results
The combined datasets contain information on 233,247 patients
who underwent breast cancer surgery. Of these, 52,483 (22.5%)
patients underwent BCT and 180,764 (77.5%) patients had BAT.
Patients included in our analysis were predominantly white
(58.9% for BCT and 53.0% for BAT), and had a median age of
62.0 years (interquartile range: 22.0 years) and 65.0 years (inter-
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quartile range: 22.0 years) for BCT and BAT, respectively. The
median comorbidity score was 2.0 (interquartile range: 6.0) for
patients undergoing BCT and BAT (Table 1).
The median lengths of hospital stay for patients undergoing
BCT and BAT were 2.0 days (interquartile range: 1.0 day) and 3.0
days (interquartile range: 2 days), respectively. Postoperative
complications were uncommon, affecting 0.5% of BCT and 0.7%
of BAT patients. Nonroutine disposition was recorded for 9.7% of
patients undergoing BCT and 13.1% of those having BAT. In-
hospital mortality was 0.1% for both BCT and BAT (Table 2).
For all outcomes except in-hospital morbidity after BAT, low-
volume providers had the worst outcomes, followed by those with
intermediate caseload, while high-volume providers had the best
outcomes (Tables 3 and 4).
In risk-adjusted multiple linear regression analysis, length of
hospital stay was significantly longer for low-volume hospitals
after BCT and BAT compared with high-volume providers (all p
£ 0.001, Table 5).
Patients who had BCT in low-volume hospitals had an odds
ratio of in-hospital mortality of 3.04 (95% CI: [1.12, 8.24],
p = 0.03) when compared with high-volume hospitals after risk-
adjusting for putative confounding factors (Table 6). For patients
who had BAT, the risk-adjusted odds ratios for in-hospital mor-
tality were 1.90 (95% CI: [0.97, 3.70], p = 0.06) for low-volume
and 1.78 (95% CI [0.95, 3.30] p = 0.07) for intermediate-volume
hospitals compared with high-volume hospitals (Table 6). Low-
volume hospitals had significantly higher postoperative compli-
cations for both BCT (OR = 1.73, 95% C1: [1.17, 2.56], p = 0.01)
Table 1. Characteristics of patients undergoing breast cancer surgery
Baseline characteristics
Breast-conserving
therapy (n = 52,483)
Breast-ablative
therapy (n = 180,764)
Age
Median (yr)
[Interquartile range]
62.0 [22.0] 65.0 [22.0]
Missing 0.02% 0.03%
Gender
Femalea 100% 100%
Race
White 58.9% 53.0%
African-American 5.6% 5.0%
Hispanic 2.6% 2.4%
Other 1.8% 1.8%
Missing 31.1% 37.8%
Income
$1–25,000 16.5% 23.2%
$25.001>–35.000 31.9% 36.1%
$35,001 and above 48.4% 37.3%
Missing 3.2% 3.4%
Median Deyo score
[interquartile range]a
2.0 [6.0] 2.0 [6.0]
Median number of
diagnosis at discharge
[interquartile range]a
2.0. [3.0] 3.0 [2.0]
Patients operated in
low-volume hospitals
12,081 (23.0%) 58,697 (32.5%)
Patients operated in
intermediate-volume
hospitals
19,549 (37.3%) 65,786 (36.4%)
Patients operated in
high-volume hospitals
20,853 (39.7%) 56,281 (31.1%)
aIndicates that there were no missing values.
Table 2. Unadjusted outcomes of patients undergoing breast surgery
Outcomes
Breast-conserving
therapy (n = 52,483)
Breast-ablative
therapy (n 180,764)
Length of stay in
days (median)
[interquartile range]
2.0 [1.0] 3.0 [2.0]
Missing 82 (0.2%) 255 (0.1%)
Mortality
Died 55 (0.1%) 159 (0.1%)
Missing 27 (0.05%) 79 (0.04%)
Postoperative complications
Present 259 (0.5%) 1,329 (0.7%)
Missing 0% 0%
Patient discharge status
Nonroutine 5,111 (9.7%) 23,705 (13.1%)
Missing 115 (0.2%) 294 (0.2%)
Table 3. Stratified unadjusted outcomes by hospital volume
Outcome Hospital volume
Unadjusted
percentages p Value
Breast-conserving therapy (n = 52,483)
Mortality < 30 0.24% <0.001
‡ 30 to < 70 0.1%
‡ 70 0.03%
Postoperative < 30 0.69% 0.002
complications ‡ 30 to < 70 0.48%
‡ 70 0.40%
Nonroutine < 30 12.2% <0.001
patient discharge ‡ 30 to <70 9.8%
‡ 70 8.3%
Breast-ablative therapy (n =180,764)
Mortality < 30 0.12% 0.001
‡ 30 to <70 0.08%
‡ 70 0.06%
Postoperative < 30 0.92% <0.001
complications ‡ 30 to <70 0.62%
‡ 70 0.67%
Nonroutine < 30 15.8% <0.001
patient discharge ‡ 30 to 70 12.8%
‡ 70 10.7%
Table 3a. Continuation
Hospital volume
Length of
hospital stay
(days) p Value
Breast-conserving
therapy (n =52,483)
< 30 2.61 < 0.001
‡ 30 to < 70 2.27
‡ 70 2.00
Breast-ablative
therapy (n = 180,764)
< 30 3.31 < 0.001
‡ 30 to < 70 3.24
‡ 70 3.18
Table 4. Unadjusted proportions of patients undergoing breast-conserv-
ing therapy by hospital volume
Hospital volume
Percentage of patients undergoing
breast-conserving therapy p Value
< 30 17.1% <0.001
‡ 30 to < 70 22.9%
> 70 26.9%
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and BAT (OR = 1.44, 95% CI: [1.21, 1.72], p < 0.001 when
compared with high-volume hospitals.
Nonroutine patient discharge was significantly higher in low
and intermediate-volume hospitals for both BCT and BAT
compared with high-volume hospitals (all p < 0.001). Finally,
patients operated on in low- (OR = 0.72; 95% CI: [0.69, 0.74], p
< 0.001) and intermediate- (OR = 0.92; 95% CI: [0.89, 0.95], p <
0.001) volume hospitals were significantly less likely to undergo
BCT compared with patients undergoing breast cancer surgery in
high-volume hospitals (Table 7).
Discussion
The present investigation, based on 13 years of nationally repre-
sentative databases, provides compelling evidence that patients
treated at high-volume hospitals have consistently better clinical
and economic outcomes such as significantly decreased length of
hospital stay, postoperative complications, nonroutine patient
discharges, and mortality. Also, our study found that patients
treated in high-volume hospitals had a significantly higher likeli-
hood of undergoing BCT, and therefore stresses the importance
of hospital volume on low-risk operations such as BCT and BAT
for localized breast cancer.
Patient outcomes have been linked to hospital volume in various
surgical diseases [1–4]. In large comprehensive studies, mortality
decreased as volume increased for major cancer operations
including colectomy, gastrectomy, esophagectomy, liver resection,
pancreatic resection, nephrectomy, and cystectomy [1, 4, 13].
These cancers are treated with high-risk operations that are
associated with significant morbidity and mortality because of their
technical complexity. Emphasis of volume–outcomes research has
been directed toward these high-risk procedures. Large differ-
ences in mortality rates between high-and low-volume providers
have been noted, resulting in many preventable surgical deaths
each year [2]. However, the impact of hospital volume on frequent
low-risk surgeries such as BCT and BAT has been poorly studied.
A few investigations have focused on the impact of hospital
volume on long-term survival for breast cancer patients [7, 14].
While Harcourt et al. [14] did not find a significant volume–out-
come relationship, Roohan et al. [7] reported that high hospital
volume was positively associated with improved 5-year survival.
This advantage remained statistically significant even after risk-
adjusting for several clinical and sociodemographic variables.
While these previous investigations evaluated a long-term outcome
of patients with breast cancer, we have attempted to delineate the
specific impact of hospital volume on the choice of treatment, in-
hospital adverse events and economic outcomes such as length of
hospital stay and rate of nonroutine patient discharge.
We found a significantly increased mortality rate after BCT in
hospitals where less than 30 cases per year were performed. Also,
postoperative in-hospital complications were significantly higher
in low-volume hospitals for both BCT and BAT. It is clear that a
patient is highly unlikely to die from breast cancer surgery in and
of itself. However, it can be hypothesized that high-volume hos-
pitals have a better pre-, peri-, and postoperative management of
patients. It is possible that the collaboration between physicians,
nursing staff, anesthesiologists, physical therapists, and other
ancillary services in high-volume centers is superior compared
with that in low-volume hospitals. This higher level of collabo-
ration between the entire team caring for the patient is likely to
decrease the in-hospital mortality.
To further elucidate the effect of hospital volume on resource
use, we evaluated outcomes such as length of hospital stay and
nonroutine patient discharge. We found that low-volume hospi-
Table 5. Risk-adjusteda associations between hospital volume and length
of hospital stay after breast cancer surgery
Hospital volume
Adjusted
estimate of
LOS (SD) p Value
Breast-conserving therapy
< 30 2.46 (0.74) < 0.001
‡ 30 to < 70 2.11 (0.67) < 0.001
‡ 70 1.93 (0.64) Ref.
Breast-ablative therapy
< 30 3.09 (0.43) <0.001
‡ 30 to < 70 2.99 (0.44) 0.34
‡ 70 2.97 (0.42) Ref
LOS = length of hospital stay, SD = standard deviation, Re-
f = High-volume providers are the reference category.
aRisk-adjusted for age, race, household income, teaching status, and
location of the hospital, and patients comorbidity.
Table 6. Risk-adjusteda associations between hospital volume and mor-
tality, postoperative complications, and nonroutine patient discharge of
breast cancer patients
Outcome Procedure volume
Adjusted
odds ratio (95% CI) p Value
Breast-conserving therapy
Mortality < 30 3.04 (1.12, 8.24) 0.03
‡ 30 to < 70 1.60 (0.59, 4.33) 0.35
‡ 70 Ref —
Postoperative < 30 1.73 (1.17, 2.56) 0.01
complications ‡ 30 to < 70 1.14 (0.81, 1.62) 0.45
‡ 70 Ref —
Nonroutine < 30 1.55 (1.40, 1.71) < 0.001
patient discharge ‡ 30 to <70 1.23 (1.13, 1.34) <0.001
‡ 70 Ref —
Breast-ablative therapy
Mortality < 30 1.90 (0.97, 3.70) 0.06
‡ 30 to <70 1.78 (0.95, 3.30) 0.07
‡ 70 Ref —
Postoperative < 30 1.44 (1.21, 1.72) <0.001
complications ‡ 30 to < 70 0.91 (0.77, 1.07) 0.26
‡ 70 Ref —
Nonroutine < 30 1.56 (1.49, 1.65) < 0.001
patient discharge ‡ 30 to < 70 1.25 (1.19, 1.31) <0.001
‡ 70 Ref —
Ref-high-volume providers are the reference category, CI = confi-
dence interval.
aRisk-adjusted for age, race, household income, teaching status and
location of the hospital, and patients comorbidity.
Table 7. Risk-adjusteda likelihood of undergoing breast-conserving ther-
apy
Procedure volume
Adjusted odds ratio of
likelihood of undergoing
breast-conserving therapy (95% CI) p Value
< 30 0.72 (0.69, 0.74) < 0.001
‡ 30 to < 70 0.92 (0.89, 0.95) <0.001
‡ 70 Ref —
Ref = high-volume providers are the reference category,
CI = Confidence interval.
aRisk-adjusted for age, race, household income, teaching status and
location of the hospital, and patients comorbidity.
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tals had a significantly higher rate of nonroutine patient dis-
charges, with risk-adjusted odds ratios exceeding 1.5 for both
BCT and BAT. Similarly, we found significantly longer lengths of
stay with decreasing hospital volume. While the risk-adjusted
difference between high- and low-volume hospitals for length of
hospital stay after BAT was small, it was more than half a day for
BCT. These results are not only statistically significant but also
important from an economic perspective, considering that longer
length of stay and increased nonroutine patient discharge are
correlated with higher costs.
Finally, we found that patients who were treated at high-volume
centers were significantly more likely to undergo BCT. It is well
established and generally accepted that BCT and mastectomy are
equally efficient regarding disease-free and overall survival in the
treatment of early-stage breast cancer [15, 16]. However, lumpec-
tomy is a less invasive procedure with better results with respect to
body image [17–20], sexual function [18, 19], and quality of life [21].
The statistically and clinically significant differences in undergoing
BCT between low- and high-volume providers are among the most
important and relevant findings of the present investigation.
The limitations of our study are those of an administrative
database analysis. First, the Nationwide Inpatient Samples data-
base contains only inpatient data, and thus long-term outcomes
such as disease-free and overall survival could not be assessed.
Second, although we performed multiple logistic and linear
regression analyses, adjusting for many potential patient and
hospital level confounders, we were unable to adjust for time of
diagnosis, tumor size, location, and grade of the breast cancer,
whether axillary lymph node dissection was performed, and
whether the patient underwent mammography screening or had
access to postoperative radiotherapy. Third, it would have been
interesting to assess the cause of death of patients who died
during hospitalization. However, this information can not be
ascertained from the Nationwide Inpatient Samples.
In summary, our study supports the conclusion that high-vol-
ume hospitals are consistently associated with better clinical and
economic outcomes for breast cancer surgery. Referral of patients
with localized breast cancer to high-volume hospitals may be
justified. It is likely that our results for breast cancer surgery can
be generalized to other low-risk surgical procedures. However,
further studies are needed to validate these assumptions.
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Appendix: Postoperative In-Hospital Morbidity
A. Mechanical wound complications:
Delayed wound healing: 998.83
Postoperative hematoma: 998.12
Disruption of operative wound: 998.3
Persistent postoperative fistula: 998.6
Emphysema resulting from procedure: 998.81
B. Infections:
Postoperative skin abscess: 998.59
Postoperative septic wound complications: 998.59
Postoperative skin infection: 998.59
Postoperative infected seroma: 998.51
C. Complications during procedure:
Accidental puncture or laceration, complicating surgery: 998.2
Foreign body accidentally left during procedure: 998.4
Bleeding complicating procedure: 998.11
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The article by Guller and colleagues (DOI: 10.1007/s00268-005-
7831-z) provides additional support to a concept that has been
building over the past few decades: high volumes yield better
outcomes. Their analysis is compelling because of the size of their
database and the number of years covered by the study. Their
findings stand on their own merits, with the primary focus on
short-term outcome results (i.e., postoperative morbidity/mortal-
ity, length of stay, and discharge status), demographics of the
patients and the hospitals, comorbidity, and the primary surgical
treatment categories for breast cancer.
The authors have correctly noted the primary limitations of their
study; a lack of outpatient and long-term outcome data. More and
more, breast-conserving therapy (BCT) is provided in the outpa-
tient setting. Breast ablative therapy (BAT) can be safely provided
on an outpatient basis, and it may be combined with a 23-hour
admission. It is not clear from the present study if 23-hour admis-
sions are part of the Nationwide Inpatient Samples (NIS) database.
What is it about high-volume hospitals that results in better
clinical and economic outcomes in the treatment of breast can-
cer? Although it appears that the data to answer this question are
not included in the NIS database, we can speculate on possible
answers. More likely than not, high-volume hospitals would (1)
attract higher numbers of specialists (including medical, radia-
tion, and surgical oncologists), (2) have more advanced technol-
ogies, and (3) have interdisciplinary breast centers or programs.
Perhaps it is these presumed other factors that give high-volume
hospitals their better short-term outcomes and different practice
patterns (i.e., a higher percentage of BCT vs. BAT). As an
example, well-organized interdisciplinary breast centers have
pretreatment planning conferences, a part of the patients selec-
tion process that generally results in increased numbers of pa-
tients being offered BCT.
Most patients facing breast cancer surgery have no way of
knowing the relative quality or the operative volumes of the
hospitals they may use for their care. Efforts have been made in
many states to publish outcome data for high-risk surgical pro-
cedures (i.e., cardiac surgery), but little has been done to publish
outcomes for low-risk procedures (i.e., breast cancer surgery).
What outcome and other data should health care purchasers and
patients have access to?
I believe the answer is to expand available national and re-
gional databases to include not only short- and long-term data
and outcomes, but also data on surgeon specialization, surgeon
case volumes, and the presence or absence of cancer specialty
programs (i.e., interdisciplinary breast centers). If these data-
bases cant be modified to include the additional outcomes and
data sets, then it may be the role of health care purchasers to
demand such information from providers of breast and other
cancer services. The benefits of such expanded databases
should be obvious for the purchasers of cancer services, but
they would also give patients more detailed insights into the
providers (i.e., hospitals, surgeons, etc.) they may chose for
their cancer care.
An appropriate way to end this commentary is to remind
ourselves of a succinct definition of quality of care prepared by
the National Institute of Medicine: ‘‘Quality of care is the degree to
which health services for individuals and populations increase the
likelihood of desired outcome and are consistent with current pro-
fessional knowledge’’ [1].
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It is difficult to peruse a modern surgical journal without seeing
articles dealing with the relationship of procedural volume and
outcomes for either the surgeons or the hospitals in which they
practice. Outcome analysis of complex procedures in general
surgery supports that the experience of the surgeon and hospital
system have major effects on both 30-day mortality and long-term
outcomes, especially when cancer-related procedures are ana-
lyzed.
Yet another in-depth analysis appears in this issue of the World
Journal of Surgery. Guller and colleagues (DOI: 10.1007/s00268-
005-7831-z), using the power of the Nationwide Inpatient Sample,
have rigorously analyzed the fate of women undergoing lumpec-
tomy and mastectomy for breast cancer and have equated out-
comes with the volume of patients treated in a particular hospital
setting. These authors have studied the adverse factors of mor-
bidity, mortality, increased hospital stay, higher percentage of
non-routine patient discharge, and the lower likelihood of per-
forming lumpectomy when indicated.
The authors report that the above adverse parameters are
linked to patients who are cared for in hospitals performing
fewer than 30 breast cancer procedures per year when com-
pared to hospitals in which more than 70 lumpectomies and
mastectomies are performed anually. The authors report the
startling finding that women who have undergone lumpectomy
at a low-volume hospital are three times more likely to die
following their procedure when compared to patients treated in
the higher volume centers! Women undergoing lumpectomy
and mastectomy have a 73% and 44% greater chance of com-
plications when treated at lower volume (less than 30 cases per
year) hospitals. It is obvious that the results of this study de-
pend on the analysis of raw data by the authors. We are left
with either accepting or rejecting their analysis. While many
surgeons performing lumpectomy would be hard pressed to
remember a patient who has died within 30 days of the pro-
cedure, the advantage (and concern) of large data sets is to
compound and accentuate differences among groups.
The authors correctly state that the analysis of low-risk proce-
dures as a result of hospital volume has not been adequately
assessed. Obviously system issues are important when the overall
management of patients is assessed. Unfortunately the cause of
mortality cannot be detected in this analysis. According to Guller
and colleagues, patients requiring breast cancer management
should be referred to and cared for in high-volume centers. These
authors further challenge us to assume that other low-risk surgical
procedures should be performed in high-volume centers.
Before payers and others working on ‘‘pay per performance’’
models take these recommendations as gospel, other analyses
using a variety of databases should be studied. It is my belief
that information from the National Cancer Database, a product
of the Commission on Cancer of the American College of
Surgeons and the American Cancer Society, will show that
community hospitals with small volumes of breast cancer pa-
tients provide excellent care for those whom they serve. Our
mission is not to recommend that patients and their referral
physicians seek care only at large-volume centers. The future of
the American healthcare system depends on constantly analyz-
ing outcomes and performance measures with the goal of
improving care at all of our inpatient facilities. It is obvious that
volume—outcome data must also be extrapolated to countries
throughout the world. The issue and challenge of applying
balanced care no matter what the size of an institution is a
major concern for our patients worldwide.
1000 World J. Surg. Vol. 29, No. 8, August 2005
